Drug Trial Radar · NCT05147805
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Aug 24, 2022
Primary completion
Mar 27, 2025
Study completion Mar 27, 2025
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Dec 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
Conditions
- Pulmonary Arterial Hypertension
Interventions
Treprostinil PalmitilDrug
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
PlaceboDrug
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Pulmonary Vascular Resistance at Week 16Time frame: Baseline to Week 16
Locations
92 sites in 17 countries. Site status is shown where the registry gives one.
USA025
Phoenix, Arizona
USA022
Scottsdale, Arizona
USA021
Tucson, Arizona
USA023
Sacramento, California
USA002
West Hollywood, California
USA008
Gainesville, Florida
USA005
Jacksonville, Florida
USA007
Orlando, Florida
USA011
Tampa, Florida
USA010
Winter Park, Florida
USA009
Atlanta, Georgia
USA006
Chicago, Illinois
USA001
Chicago, Illinois
USA013
Indianapolis, Indiana
USA014
Iowa City, Iowa
USA003
Kansas City, Kansas
USA102
New York, New York
USA017
New York, New York
USA016
Dallas, Texas
USA012
Denison, Texas
USA018
Houston, Texas
ARG004
Córdoba, Argentina
ARG001
Córdoba, Argentina
ARG008
Cuiudad Autónoma de Buenos Aires, Argentina
ARG009
Quilmes, Buenos Aires, Argentina
ARG002
Rosario, Santa Fe Province, Argentina
ARG006
Rosario, Santa Fe Province, Argentina
ARG007
San Miguel de Tucumán, Tucumán Province, Argentina
AUS005
New Lambton Heights, New South Wales, Australia
AUS004
Milton, Queensland, Australia
AUS001
Woolloongabba, Queensland, Australia
AUS003
Adelaide, South Australia, Australia
AUS002
Hobart, Tasmania, Australia
AUT001
Vienna, Austria
AUT002
Linz, Upper Austria, Austria
BEL001
Liège, Belgium
BEL003
Anderlecht, Brussels Capital, Belgium
BEL002
Leuven, Vlaams Brabant, Belgium
BRA001
São Paulo, Brazil
BRA003
Belo Horizonte, Minas Gerais, Brazil
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.